AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.

The agreement, to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs is the largest of its ...

By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related ...

AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to ...

By Andrew MacAskill and Maggie Fick BEIJING/LONDON, Jan 29 (Reuters) - UK drugmaker AstraZeneca will invest $15 billion in ...

Under the deal, the FTSE 100 group will have the exclusive global rights, outside China, to CSPC's once-a-month jab that is ...

British pharmaceutical group AstraZeneca said Thursday that it would invest $15 billion in China through 2030 to expand its ...

AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...

AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, despite keeping its options open. | AstraZeneca is showing no signs of ...

This investment coincides with China’s burgeoning presence in the pharmaceutical industry, driven by an uptick in innovative medicines R&D.

AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.

AstraZeneca said it entered into a collaboration agreement with China's CSPC Pharmaceuticals to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs, in a deal potentially ...